新葡萄京娱乐场手机版

2020
May 2020

新葡萄京娱乐场手机版NMPA accepted the application for anti PD-1 monoclonal antibody penpulimab (AK105)

Apr 2020

新葡萄京娱乐场手机版HKEX Listing(Stock Code: 9926)

2019
Aug 2019

新葡萄京娱乐场手机版We established CTTQ-Akeso

Jun 2019

We formed Sino Biopharm Collaboration to codevelop and co-commercialize penpulimab (AK105)

新葡萄京娱乐场手机版We obtained the IND approval for a clinical trial of AK112 (PD-1/VEGF) in theUnited States

Mar 2019

We obtained the IND approval for AK104 from the FDA to begin a Phase Ib/II clinical trial in the United States

Jan 2019

新葡萄京娱乐场手机版The Company was incorporated in the Cayman

Islands as an exempted company with limited liability

2018
May 2018

We initiated a Phase I clinical trial of ebronucimab (AK102) (PCSK9) in China

Mar 2018

We obtained the IND approval for penpulimab (AK105) with respect to cervical cancer and solid tumors from the FDA in the United States

Jan 2018

We initiated a Phase I clinical trial for AK101 (IL-12/IL-23)  in China

2017
Dec 2017

新葡萄京娱乐场手机版We initiated a Phase I clinical trial for penpulimab (AK105) (PD-1) in  Australia

Oct 2017

We initiated a Phase I clinical trial (with chemotherapy) for AK104 (PD-1/CTLA-4) for the treatment of solid tumors in Australia

2015
Nov 2015

We out-licensed AK107 (CTLA-4) to Merck (code name in Merck is MK1308)

2012
Apr 2012

新葡萄京娱乐场手机版We initiated the development of innovative ACE Platform and “TETRABODY” technology

Mar 2012

新葡萄京娱乐场手机版Akeso Biopharma (中山康方生物醫藥有限公司), our principal operating entity, was established in Zhongshan, China

澳门十三第娱乐场网站-新葡萄京娱乐场手机版 奥门永利总站网址-新葡萄京娱乐场手机版 365bet体育备用网址-新葡萄京娱乐场手机版 澳门威尼斯人app-新葡萄京娱乐场手机版 澳门新葡亰平台游戏-新葡萄京娱乐场手机版 72779太阳集团游戏-新葡萄京娱乐场手机版 威尼斯app下载-新葡萄京娱乐场手机版 亚洲城手机版入口-新葡萄京娱乐场手机版 72779太阳集团游戏-新葡萄京娱乐场手机版 188金宝搏官网下载-新葡萄京娱乐场手机版 188金宝搏官网登录-新葡萄京娱乐场手机版 188金宝搏官网-新葡萄京娱乐场手机版 ju111 net九州手机版-新葡萄京娱乐场手机版 365bet官方投注-新葡萄京娱乐场手机版 bv1946伟德备用-新葡萄京娱乐场手机版 澳门游戏平台大全-新葡萄京娱乐场手机版 千亿体育app-新葡萄京娱乐场手机版 美高梅官方网站-新葡萄京娱乐场手机版 OG东方厅app-新葡萄京娱乐场手机版 澳门威斯人7026com-新葡萄京娱乐场手机版